Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: weight

Mechanistic, Epidemiologic Clues Suggest Possible Link Between Obesity, Inflammation in Rheumatoid Arthritis

Kurt Ullman  |  October 11, 2016

Obesity has an established systemic inflammatory component. Could that be a trigger for the inflammation seen in rheumatoid arthritis (RA) and other rheumatic diseases? Although there is no direct scientific evidence, both mechanistic and epidemiologic clues do give some intriguing suggestions of a possible link. “At first, we thought that fat was involved only in…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:epidemiologicinflammationlinkObesityPathogenesisResearchRheumatoid arthritisrisk factor

Rheumatoid Arthritis Research Provides New Insights on Risk Factors, Identification Tools, Intervention

Rheumatoid Arthritis Research Provides New Insights on Risk Factors, Identification Tools, Intervention

Susan Bernstein  |  October 11, 2016

Established wisdom holds that patients with rheumatoid arthritis (RA) will fare better if their disease is diagnosed as early as possible, and treatments with disease-modifying drugs are started before inflammation can do more damage to joints and tissue. Usually, early diagnosis means spotting the clinical signs of disease, but new research tells us more about…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:identificationinterventionPathogenesispatient careResearchRheumatoid arthritisrheumatologyRisk Factors

The Impact of U.S. Supreme Court Decisions on Medical Affairs, Healthcare Policy

Simon M. Helfgott, MD  |  October 11, 2016

As America’s capital, Washington, D.C., maintains an outsized influence in our daily lives. Despite having a meager sliver of the New York City population, the daily political transactions that transpire in the District of Columbia impact our lives. The comings and goings in the corridors of Congress are likely to have a greater impact on us…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:Affordable Care Act (ACA)BRCADNAgeneHealth carejudiciarylawsLegislationmedicalSupreme CourtVermont

State-of-the-Art Course on Interprofessional Management of Rheumatoid Arthritis

Maura Iversen  |  October 11, 2016

During an interactive, case-based course at the 2016 ACR/ARHP Annual Meeting, participants will develop strategies to help patients manage unique barriers to access to care and adherence…

Filed under:ConditionsEducation & TrainingPediatric ConditionsProfessional Topics Tagged with:ACR/ARHPACR/ARHP Annual MeetingAssociation of Rheumatology Professionals (ARP)EducationelderlyPediatricRheumatiod arthritis

Management of Psoriatic Arthritis, Treatment of Axial Spondyloarthritis Addressed at EULAR 2016

Thomas R. Collins  |  October 10, 2016

LONDON—Rheumatologists need to make the management of psoriatic arthritis (PsA) “a little more complex,” treating different tissues individually and doing more to help treat and prevent co-morbidities, an expert said here at the Annual Congress of the European League Against Rheumatism (EULAR) 2016. Iain McInnes, MD, PhD, director of the Research Institute for Infection, Immunity…

Filed under:ConditionsMeeting ReportsPsoriatic Arthritis Tagged with:axial spondyloarthritis (SpA)Disease-modifying antirheumatic drugs (DMARDs)EULARManagementpatient carePsoriatic ArthritisrheumatologyTreatment

Preclinical Phases of Rheumatoid Arthritis Better Understood

Thomas R. Collins  |  October 10, 2016

LONDON—Research continues to advance in understanding the causes, prediction and management of the stages of early arthritis before full-blown clinical disease, and an expert highlighted some of the latest of these encouraging findings at the Annual Congress of the European League Against Rheumatism (EULAR) 2016. Many of the genetic and environmental risk factors are known,…

Filed under:ConditionsMeeting ReportsResearch RheumRheumatoid Arthritis Tagged with:CauseEULARManagementPathogenesispreclinicalResearchRheumatoid arthritisrisk

Is Fibromyalgia Overdiagnosed?

Susan Bernstein  |  October 10, 2016

Are too many patients diagnosed with fibromyalgia? The co-authors of one new study believe that close to 75% of patients who have received a clinical fibromyalgia diagnosis do not meet the 2010 Preliminary American College of Rheumatology (ACR) Criteria for Fibromyalgia.1 They say these patients are false-positive and may be taking treatments they don’t need….

Filed under:ConditionsPain SyndromesResearch Rheum Tagged with:ClinicalcriteriademographicsDiagnosisFibromyalgiaPainpatient careResearch

Rheumatology Coding Corner Question: Gout Visit for Established Patient

From the College  |  October 10, 2016

A 55-year-old female patient returns to the office with complaints of gout pain. She is complaining of swelling and a burning pain in her left toe. She has been taking an over-the-counter NSAID to treat the pain, but this has done little to alleviate it. This is her second flare this year. The patient denies…

Filed under:Billing/CodingConditionsFrom the CollegeGout and Crystalline ArthritisOther Rheumatic ConditionsPractice Support Tagged with:BillingCodingGoutoffice visitpatient carePractice Managementrheumatologistrheumatology

FDA Approves Ustekinumab for Crohn’s Disease

Reuters Staff  |  September 26, 2016

(Reuters)—Johnson & Johnson says on Monday that the U.S. Food and Drug Administration approved the company’s psoriasis drug, ustekinumab (Stelara), for use in adults with Crohn’s disease. The drug is approved in the U.S. to treat plaque psoriasis and a type of arthritis associated with psoriasis. Crohn’s is a chronic inflammatory condition in the gastrointestinal…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Crohn's diseaseFDAFood and Drug Administrationinflammatory bowel diseaseustekinumab

Research on Ixekizumab in Psoriatic Arthritis and More Presented at EULAR 2016

Thomas R. Collins  |  September 12, 2016

LONDON—Results from the extension phase of a Phase 3 trial for the IL-17A inhibitor ixekizumab in psoriatic arthritis (PsA) show that patients started on placebo, adalimumab and ixekizumab continued to show improvements in arthritis, dactylitis and ethesitis, said Philip Mease, MD, a rheumatologist at Swedish Medical Center University of Washington in Seattle.1 Dr. Mease presented the…

Filed under:ConditionsDrug UpdatesOther Rheumatic ConditionsPsoriatic ArthritisResearch Rheum Tagged with:adalimumabDisease-modifying antirheumatic drugs (DMARDs)EULAREuropean League Against RheumatismixekizumabPsoriatic ArthritisResearchsecukinumabTreatment

  • « Previous Page
  • 1
  • …
  • 56
  • 57
  • 58
  • 59
  • 60
  • …
  • 93
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences